Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Debiopharm International S A has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution involves 1 distinct examiner and 1 distinct art unit. YOUNG, MICAH PAUL is the busiest examiner, with 1 pending office action. This single pending matter defines the current prosecution landscape for the entity within this technical field.
The 1 to 1 ratio between pending office actions and distinct examiners shows that the company's current prosecution is entirely concentrated under YOUNG, MICAH PAUL. As the busiest examiner, he is responsible for the only active matter in the Biotechnology & Pharmaceuticals area. The involvement of 1 distinct art unit indicates that the technical review is focused within a single specialized group. This centralized prosecution means that the company is currently interacting with only 1 examiner and 1 art unit. Practitioners should note that there is no spread of matters across multiple officials, as the 1 pending action represents the entirety of the company's active workload. This focused activity suggests a specific patent objective for the current period, with the 1 pending office action being the sole focus of the company's efforts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOUNG, MICAH PAUL | 1 | 55.2% | +30.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18853800 | NOVEL COMPOSITION | YOUNG, MICAH PAUL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18853800 | NOVEL COMPOSITION | YOUNG, MICAH PAUL | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18853800 | NOVEL COMPOSITION | YOUNG, MICAH PAUL | 1618 | §103§112 | Non-Final OA | — | Pending | Oct 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDebiopharm International S A has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Micah Paul Young has the most, with 1 of Debiopharm International S A's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
